FDA Approves PharmaEssentia’s BESREMi^® (ropeginterferon alfa-2b-njft) for Adults with Essential Thrombocythemia, A Rare Blood Cancer

PharmaEssentia USA Corporation announced the US FDA has approved BESREMi^® for the treatment of adults with essential thrombocythemia (ET), making it the first new FDA-approved treatment for ET in nearly three decades.